{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:32Z","timestamp":1792723112306,"version":"4.5.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e00952","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:14:28Z","timestamp":1782335668000},"page":"e00952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in the management of pediatric low-grade glioma"],"prefix":"10.1016","volume":"23","author":[{"given":"Meziane","family":"Brizini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Perreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.neurot.2026.e00952_bib1","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","article-title":"CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/neuonc\/noq178","article-title":"Survival and long-term health and cognitive outcomes after low-grade glioma","volume":"13","author":"Armstrong","year":"2011","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00952_bib3","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","article-title":"Response assessment in paediatric low-grade glioma: recommendations from the response assessment in pediatric neuro-oncology (RAPNO) working group","volume":"21","author":"Fangusaro","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/neuonc\/noad195","article-title":"Pediatric low-grade glioma: state-of-the-art and ongoing challenges","volume":"26","author":"Fangusaro","year":"2024","journal-title":"Neuro Oncol"},{"issue":"29","key":"10.1016\/j.neurot.2026.e00952_bib5","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00952_bib6","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the children's oncology group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00952_bib7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.21091","article-title":"Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction","volume":"103","author":"Lafay-Cousin","year":"2005","journal-title":"Cancer"},{"issue":"16_suppl l","key":"10.1016\/j.neurot.2026.e00952_bib8","article-title":"Late mortality and morbidity among adult survivors of childhood glioma treated over three decades: a report from the childhood cancer survivor study","volume":"40","author":"Blank","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib9","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S1470-2045(12)70577-6","article-title":"Molecular diagnostics in paediatric glial tumours","volume":"14","author":"Kim","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00952_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1750-3639.2008.00225.x","article-title":"Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene","volume":"19","author":"Sievert","year":"2009","journal-title":"Brain Pathol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00952_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13060","article-title":"The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors","volume":"32","author":"Bale","year":"2022","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-024-04857-2","article-title":"Targeting the RAS\/MAPK pathway in children with glioma","volume":"171","author":"Cacciotti","year":"2025","journal-title":"J Neuro Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00952_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-24-3439","article-title":"FDA approval summary: tovorafenib for relapsed or refractory BRAF-altered pediatric low-grade glioma","volume":"31","author":"Singh","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00952_bib14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-23-1503","article-title":"FDA approval summary: Dabrafenib in combination with trametinib for BRAFV600E mutation-positive low-grade glioma","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11060-024-04672-9","article-title":"Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines","volume":"168","author":"Kocher","year":"2024","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib17","article-title":"Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition","volume":"4","author":"Nobre","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00952_bib18","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3390\/curroncol31070299","article-title":"Canadian consensus for treatment of BRAF V600E mutated pediatric and AYA gliomas","volume":"31","author":"Erker","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1417484","article-title":"BRAF\/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country","volume":"14","author":"Abu Laban","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00952_bib20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib21","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-025-61820-z","article-title":"A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas","volume":"16","author":"Apfelbaum","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00952_bib22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00952_bib23","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00952_bib24","first-page":"475","article-title":"FGFR-TACC gene fusions in human glioma","volume":"19","author":"Lasorella","year":"2017","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00952_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11910-023-01257-3","article-title":"Treatment of pediatric low-grade gliomas","volume":"23","author":"Sait","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00952_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051152","article-title":"Pediatric low-grade gliomas","volume":"12","author":"Collins","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1016\/j.neurot.2026.e00952_bib27","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 12","key":"10.1016\/j.neurot.2026.e00952_bib28","article-title":"An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer","volume":"16","author":"Ryall","year":"2015","journal-title":"BMC Genom"},{"issue":"Supplement_3","key":"10.1016\/j.neurot.2026.e00952_bib29","doi-asserted-by":"crossref","first-page":"iii3","DOI":"10.1093\/noajnl\/vdaf166.013","article-title":"5 association of FGFR1 oncogenic alterations and spontaneous hemorrhage in low-grade gliomas","volume":"7","author":"Brizini","year":"2025","journal-title":"Neuro-Oncology Advances"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40478-020-00980-z","article-title":"Molecular and clinicopathologic features of gliomas harboring NTRK fusions","volume":"8","author":"Torre","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10014-024-00494-9","article-title":"Tectal glioma: clinical, radiological, and pathological features, and the importance of molecular analysis","volume":"42","author":"Imoto","year":"2025","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40478-018-0602-5","article-title":"Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis","volume":"6","author":"Liu","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e00952_bib33","first-page":"1","article-title":"Pediatric-type diffuse low grade glioma","volume":"167","author":"Kotch","year":"2025","journal-title":"Adv Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00401-024-02803-0","article-title":"MYB\/MYBL1-altered gliomas frequently harbor truncations and non-productive fusions in the MYB and MYBL1 genes","volume":"148","author":"Chung","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00952_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jnen\/nlac123","article-title":"MYB\/MYBL1::QKI fusion-positive diffuse glioma","volume":"82","author":"Suh","year":"2023","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/neuonc\/noac132","article-title":"Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics","volume":"25","author":"Yeo","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00952_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoncol.2024.5506","article-title":"Molecular testing for the world health organization classification of central nervous system tumors: a review","volume":"11","author":"Horbinski","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib38","article-title":"IDH-Mutant gliomas in children and adolescents - from biology to clinical trials","volume":"14","author":"Evans","year":"2024","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00952_bib39","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s00381-024-06504-7","article-title":"Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era","volume":"40","author":"Plant-Fox","year":"2024","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12885-024-11820-x","article-title":"LOGGIC\/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration","volume":"24","author":"van Tilburg","year":"2024","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00952_bib43","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-11-0127","article-title":"Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas","volume":"17","author":"Jacob","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00952_bib44","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1078-0432.CCR-18-1965","article-title":"The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma","volume":"25","author":"Buhl","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00952_bib45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00952_bib46","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1\u2013FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"issue":"16_suppl l","key":"10.1016\/j.neurot.2026.e00952_bib47","article-title":"Erdafitinb in patients with FGFR-altered tumors: results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B)","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib48","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: Overview, prevention, and management guidelines","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.neurot.2026.e00952_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1399356","article-title":"Case report: slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child","volume":"14","author":"Brizini","year":"2024","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00952_bib50","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib51","article-title":"Long-term efficacy and safety of larotrectinib in pediatric patients with trk fusion primary central nervous system (CNS) tumors: an updated analysis","author":"Doz","year":"2025","journal-title":"Abstracts from the 57th Congress of the International Society of Paediatric Oncology (SIOP) October 20-23, 2025: Pediatr Blood Cancer"},{"key":"10.1016\/j.neurot.2026.e00952_bib52","series-title":"FDA expands pediatric indication for entrectinib and approves new pellet formulation","year":"2023"},{"key":"10.1016\/j.neurot.2026.e00952_bib53","series-title":"FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00952_bib54","series-title":"A study of repotrectinib in pediatric and young adult subjects harboring ALK, ROS1, OR NTRK1-3 alterations (NCT04094610)","year":"2025"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00952_bib55","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s00381-024-06639-7","article-title":"Molecular markers for pediatric low-grade glioma","volume":"40","author":"Levine","year":"2024","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-019-02078-w","article-title":"Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course","volume":"139","author":"Wefers","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s40478-025-02070-4","article-title":"The malignant transformation of an atypical angiocentric glioma, MYB-altered","volume":"13","author":"Aboubakr","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e00952_bib58","series-title":"FDA approves vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation","year":"2024"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00952_bib59","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(25)00472-3","article-title":"Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-bind, placebo-controlled, phase 3 trial","volume":"26","author":"Cloughesy","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00401-025-02935-x","article-title":"Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors","volume":"150","author":"Nandakumar","year":"2025","journal-title":"Acta Neuropathol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib61","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-23-4033","article-title":"Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors","volume":"30","author":"Hansford","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00952_bib62","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of germline genetic testing panels in patients with cancer: ASCO guideline","volume":"42","author":"Tung","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1470-2045(24)00640-5","article-title":"The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study","volume":"26","author":"Negm","year":"2025","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00952_bib64","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1001\/jamaoncol.2021.4536","article-title":"Performance of the McGill interactive pediatric OncoGenetic guidelines for identifying cancer predisposition syndromes","volume":"7","author":"Goudie","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib65","article-title":"Germline cancer predisposition results from the national cancer institute-children's oncology group pediatric MATCH trial","volume":"9","author":"Scollon","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00952_bib66","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMra2116344","article-title":"Brain tumors in children","volume":"386","author":"Cohen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00952_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1","volume":"56","author":"Carton","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00952_bib68","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a pediatric brain tumor consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.neurot.2026.e00952_bib69","article-title":"Children's oncology Group's 2023 blueprint for research: central nervous system tumors","volume":"70","author":"Leary","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00952_bib70","first-page":"5636","article-title":"Ttype 1-associated optic pathway gliomas: pathogenesis and emerging treatments","volume":"27","author":"Amato","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00952_bib71","article-title":"Rapamycin and rapalogs for Tuberous sclerosis complex","volume":"7","author":"Sasongko","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00952_bib72","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"Franz","year":"2015","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00952_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with Tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00952_bib74","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pediatrneurol.2025.04.007","article-title":"Long-term efficacy and safety of mammalian target of rapamycin inhibitor treatment for subependymal giant cell astrocytoma in tuberous sclerosis","volume":"168","author":"Becker","year":"2025","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13023-023-02982-1","article-title":"Effectiveness and safety of everolimus treatment in patients with Tuberous sclerosis complex in real-world clinical practice","volume":"18","author":"Cockerell","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00952_bib76","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with Tuberous sclerosis complex: 2-Year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00952_bib77","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14737175.2025.2472922","article-title":"Treating subependymal giant cell astrocytoma in patients with Tuberous sclerosis complex: an update of the literature","volume":"25","author":"Ritter","year":"2025","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00952_bib78","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00401-020-02144-8","article-title":"Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features","volume":"139","author":"Sloan","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"15_suppl","key":"10.1016\/j.neurot.2026.e00952_bib79","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1200\/JCO.2019.37.15_suppl.1517","article-title":"Gliomas in the context of Li-Fraumeni syndrome: an international cohort","volume":"37","author":"Michaeli","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib80","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2026.e00952_bib81","article-title":"Prospective study of annual whole-body magnetic resonance imaging as part of a multimodality screening program for individuals with Li-Fraumeni syndrome","volume":"9","author":"Maoz","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib82","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib83","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041584","article-title":"New paradigms in the clinical management of Li-Fraumeni syndrome","volume":"14","author":"Giovino","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/2159-8290.CD-23-0456","article-title":"Early cancer detection in Li-Fraumeni syndrome with cell-free DNA","volume":"14","author":"Wong","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.neurot.2026.e00952_bib85","series-title":"GeneReviews((R))","article-title":"Noonan syndrome","author":"Roberts","year":"1993"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00952_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10080582","article-title":"Low-grade gliomas in patients with Noonan syndrome: case-based review of the literature","volume":"10","author":"Lodi","year":"2020","journal-title":"Diagnostics"},{"issue":"9863","key":"10.1016\/j.neurot.2026.e00952_bib87","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00952_bib88","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-24-1611","article-title":"Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis type 1, Noonan syndrome, CBL syndrome, Costello syndrome, and related RASopathies","volume":"30","author":"Perrino","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00952_bib89","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1158\/0008-5472.CAN-20-0916","article-title":"The emerging role of ras pathway signaling in pediatric cancer","volume":"80","author":"Ney","year":"2020","journal-title":"Cancer Res"},{"issue":"31","key":"10.1016\/j.neurot.2026.e00952_bib90","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1073\/pnas.1511694112","article-title":"Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00952_bib91","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/WCO.0000000000000869","article-title":"Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies","volume":"33","author":"Escudero","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00952_bib92","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/neuonc\/noac035","article-title":"Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients","volume":"24","author":"Miller","year":"2022","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112683","article-title":"The clinical applications of liquid biopsies in pediatric brain tumors: a systematic literature review","volume":"14","author":"Greuter","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib94","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","article-title":"Serial assessment of measurable residual disease in medulloblastoma liquid biopsies","volume":"39","author":"Liu","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neurot.2026.e00952_bib95","series-title":"Central nervous system cancers","year":"2025"},{"key":"10.1016\/j.neurot.2026.e00952_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/1545-5017.70093","article-title":"Cerebrospinal fluid liquid biopsy enables targeted therapy without tissue diagnosis in pediatric low-grade gliomas with BRAF V600E mutation","author":"Sultan","year":"2026","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00952_bib97","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/neuonc\/noab299","article-title":"Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine","volume":"24","author":"Pages","year":"2022","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/1545-5017.70069","article-title":"Detection of tumor-specific variants in CSF of children with brain tumors, including low-grade and cytology-negative cases","volume":"73","author":"Usami","year":"2026","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.neurot.2026.e00952_bib99","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4939-9164-8_6","article-title":"Analyzing cerebrospinal fluid proteomes to characterize central nervous system disorders: a highly automated mass spectrometry-based pipeline for biomarker discovery","volume":"1959","author":"Nunez Galindo","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00952_bib100","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/neuonc\/noac264","article-title":"Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification","volume":"25","author":"Zuccato","year":"2023","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00952_bib101","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ana.27291","article-title":"Cerebrospinal fluid metabolome in central nervous system infections: a study of diagnostic accuracy","volume":"98","author":"Staal","year":"2025","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-024-02842-7","article-title":"Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method","volume":"149","author":"Madlener","year":"2025","journal-title":"Acta Neuropathol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib103","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/S1470-2045(25)00489-9","article-title":"Artificial intelligence for response assessment in pediatric neuro-oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translation","volume":"26","author":"Kazerooni","year":"2025","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00952_bib104","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/neuonc\/noae093","article-title":"Towards consistency in pediatric brain tumor measurements: challenges, solutions, and the role of artificial intelligence-based segmentation","volume":"26","author":"Familiar","year":"2024","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib105","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/S1470-2045(25)00484-X","article-title":"Artificial intelligence for response assessment in pediatric neuro-oncology (AI-RAPNO), part 1: review of the current state of the art","volume":"26","author":"Kann","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00952_bib106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00234-018-1979-3","article-title":"Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements","volume":"60","author":"D'Arco","year":"2018","journal-title":"Neuroradiology"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e00952_bib107","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.2024.42.16_suppl.2066","article-title":"Deciphering pediatric low-grade glioma trajectories: deep learning\u2013based volumetrics for patients under surveillance","volume":"42","author":"Pardo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2025.123742","article-title":"Performance of machine learning models in predicting BRAF alterations using imaging data in low-grade glioma: a systematic review and meta-analysis","volume":"195","author":"Firouzabadi","year":"2025","journal-title":"World Neurosurg"},{"key":"10.1016\/j.neurot.2026.e00952_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107478","article-title":"Radiomics features based on MRI predict BRAF V600E mutation in pediatric low-grade gliomas: a non-invasive method for molecular diagnosis","volume":"222","author":"Xu","year":"2022","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00952_bib110","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1007\/s00259-022-05817-6","article-title":"Joint EANM\/SIOPE\/RAPNO practice guidelines\/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0","volume":"49","author":"Piccardo","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00952_bib111","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/neuonc\/noab096","article-title":"Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors","volume":"23","author":"Marner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00952_bib112","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1007\/s00259-025-07377-x","article-title":"Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET","volume":"52","author":"Rosen","year":"2025","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00952_bib113","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1007\/s00381-024-06532-3","article-title":"Role of intraoperative ultrasound and MRI to aid grade of resection of pediatric low-grade gliomas: accumulated experience from 4 centers","volume":"40","author":"Dietvorst","year":"2024","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib114","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10143-025-03631-w","article-title":"Efficacy and safety of intraoperative magnetic resonance imaging for low-grade and high-grade gliomas: an updated systematic review and meta-analysis","volume":"48","author":"Baptista","year":"2025","journal-title":"Neurosurg Rev"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00381-025-06810-8","article-title":"5-Aminolevulinic acid (5-ALA) in paediatric brain tumour surgery-a systematic review and exploration of fluorophore alternatives","volume":"41","author":"Collins","year":"2025","journal-title":"Childs Nerv Syst"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00952_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213677","article-title":"Utility and safety of 5-ALA guided surgery in pediatric brain tumors: a systematic review","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neurot.2026.e00952_bib117","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ajo.2025.09.028","article-title":"Evaluating the role of virtual reality visual fields (VRF) in the diagnosis and management of pediatric neuro-ophthalmic conditions","volume":"281","author":"Saleem","year":"2026","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00952_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2024.103933","article-title":"Pilot study comparing a new virtual reality-based visual field test to standard perimetry in children","volume":"28","author":"Mesfin","year":"2024","journal-title":"J AAPOS"},{"key":"10.1016\/j.neurot.2026.e00952_bib119","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpeds.2019.06.021","article-title":"Visual acuity assessment and vision screening using a novel smartphone application","volume":"213","author":"Zhao","year":"2019","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00952_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305548","article-title":"Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas","volume":"19","author":"Arnljots","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00952_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217640","article-title":"Pediatric gliomas immunity challenges and immunotherapy advances","volume":"618","author":"Vetsika","year":"2025","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib122","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1038\/s41467-020-18070-y","article-title":"Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity","volume":"11","author":"Grabovska","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib123","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41467-024-49595-1","article-title":"Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment","volume":"15","author":"Levine","year":"2024","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00952_bib124","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177413","article-title":"Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma","volume":"134","author":"Tripathi","year":"2024","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00952_bib125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"Okada","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib126","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-5-67","article-title":"Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas","volume":"5","author":"Okada","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.neurot.2026.e00952_bib127","article-title":"The clinical utility of a tiered approach to pediatric glioma molecular characterization for resource-limited settings","volume":"10","author":"Hammad","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00952_bib128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-025-05056-3","article-title":"Financial toxicity in pediatric and adolescent neurosurgical oncology","volume":"174","author":"Giantini-Larsen","year":"2025","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00952_bib129","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2022.09.036","article-title":"Paediatric strategy forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the european medicines agency with participation of the food and drug administration","volume":"177","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00952_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:57:06Z","timestamp":1792720626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926001224"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00952","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the management of pediatric low-grade glioma","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00952"}}